問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

Chi Mei Hospital, Liouying (在職)

Division of Hematology & Oncology

Division of Urology

National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of General Surgery

National Health Research Institutes (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

陳尚鴻Chen, Shang-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years

Recruiting Trial

86Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳尚鴻

List

149Cases

2025-10-01 - 2028-12-31

Phase I/II

Not yet recruiting
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)

  • Condition/Disease

    Colorectal Cancer (Diagnosis)

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
7Sites

Recruiting7Sites

2023-08-01 - 2029-01-17

Phase III

Active
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  • Condition/Disease

    Colonic Neoplasms

  • Test Drug

    Injection

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2023-12-01 - 2027-03-31

Phase II

Active
A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab and to Evaluate Safety and Efficacy of ABBV-400 in Combination With Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer

  • Condition/Disease

    Unresectable Metastatic Colorectal Cancer

  • Test Drug

    N/A N/A N/A N/A N/A

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting1Sites

2024-03-15 - 2032-12-31

Phase III

Active
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

  • Condition/Disease

    Breast Neoplasms

  • Test Drug

    Frozen crystal injections and suspensions for injection Frozen crystal powder for injection

Participate Sites
6Sites

Recruiting6Sites

2024-06-01 - 2027-12-31

Phase I

Active
A Phase 1, First-in-Human, Open-label, Doseescalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 in Subjects With Advanced Solid Tumors

  • Condition/Disease

    Metastatic Solid Tumor

  • Test Drug

    Injectable

Participate Sites
3Sites

Recruiting3Sites

2024-06-30 - 2029-06-30

Phase II

Active
Phase II Study of Tislelizumab Combined With Induction Chemoradiotherapy and Subsequent Conversion Surgery for Locally Advanced Unresectable ESCC

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma (ESCC)

  • Test Drug

    Injectable

Participate Sites
8Sites

Recruiting8Sites

2024-07-15 - 2026-08-31

Phase I

Active
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Advanced or Metastatic Solid Tumors

  • Test Drug

    Injectable

Participate Sites
4Sites

Recruiting4Sites

2024-07-31 - 2031-12-31

Phase III

Active
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

  • Condition/Disease

    Advanced Breast Cancer

  • Test Drug

    Tablets

Participate Sites
7Sites

Recruiting7Sites

2024-09-01 - 2032-12-31

Phase III

Active
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  • Condition/Disease

    Colorectal Neoplasms

  • Test Drug

    Injectables

Participate Sites
5Sites

Recruiting5Sites

2025-02-11 - 2038-02-19

Phase III

Active
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

  • Condition/Disease

    Breast Cancer

  • Test Drug

    Tablets Capsules Tablets Tablets Tablets

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB